Table 2.
Compliance of prostate and breast cancer therapy.
| Prostate pathways | Number of cases | Percent usage (N = 292) January 2010–March 2011 |
|---|---|---|
| Prostate EBRT | 124 | 42 |
| Prostate EBRT + brachy | 25 | 9 |
| Prostate brachytherapy | 84 | 29 |
| Prostate post_prostatectomy | 30 | 10 |
| prostate RTOG 0815 EBRT alone | 8 | 3 |
| Prostate RTOG 0815 brachy + EBRT | 12 | 4 |
| SBRT prostate | 5 | 2 |
| Non-compliant (does not use any of the above pathways) | 4 | 1 |
| Breast pathways | Number of cases | Percent usage (N = 155) January 2011–February 2012 |
| Breast brachytherapy (mammosite) | 12 | 8 |
| Breast Canadian tangents (prone or supine) | 57 | 37 |
| Breast standard tangents (prone or supine) | 58 | 37 |
| Breast tangents nodes + boost | 6 | 4 |
| Breast post mastectomy | 14 | 9 |
| Breast RTOG_1005_standard boost | 3 | 2 |
| Non-compliant (does not use any of the above pathways) | 5 | 3 |